Neuphoria FY26 loss widens to $13.59 million; revenue drops 92.5% to $1.17 million
NEUP•FY26 loss widens as revenue falls
Neuphoria posted a pre-tax loss of USD 13.59 million, widening from USD 0.84 million a year earlier.
Revenue fell 92.5% to USD 1.17 million, versus a year-ago period that included a USD 15 million Merck milestone.
Expenses, restructuring costs and impairment
Research and development expense dropped 60.6% to USD 3.55 million, while general and administrative costs edged down 4.3% to USD 7.44 million.
Results included USD 1.28 million of restructuring costs after an October 2025 plan to pause BNC210 work and cut headcount.
Other income climbed to USD 2.86 million, and the company recorded a USD 5.36 million goodwill impairment tied to Merck’s MK-1167 trial cancellation.
